During the past decade, Covance Clinical Research Unit - Dr. Andrew Ahmann conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Covance Clinical Research Unit - Dr. Andrew Ahmann" are "Type 2 Diabetes" (2 trials). Many other conditions were trialed in "Covance Clinical Research Unit - Dr. Andrew Ahmann" in a lesser frequency.

Most popular intervention types in "Covance Clinical Research Unit - Dr. Andrew Ahmann" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "DIO-902" (2 trials) and "DIO-902 placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Covance Clinical Research Unit - Dr. Andrew Ahmann" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Covance Clinical Research Unit - Dr. Andrew Ahmann". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Covance Clinical Research Unit - Dr. Andrew Ahmann, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Covance Clinical Research Unit - Dr. Andrew Ahmann, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".